Our laboratory is located in Canada’s capital, where our team pursues interdisciplinary research on Parkinson’s-related topics: (i) building animal models of pathogenesis, as informed by findings in patients’ brains; (ii) exploring drug targets; and (iii) pursuing biomarker studies for disease prediction. Under (i), we mostly focus on the function of four PD genes: -synuclein (SNCA); acid -glucocerebrosidase-1 (GBA); leucine-rich repeat kinase-2 (LRRK2); and Parkin (PARK2). Our lab currently has 10 full-time members. My responsibilities include to: lead a research group (50%); deliver patient care (20%); direct the OHRI’s Neuroscience Program (20%); and oversee the university’s MD/PhD Program (10%).